Abstract

We investigated the clinical response of chronic heart failure patients with β2-adrenergic receptor Gln27→Glu polymorphism treated for 6 months with carvedilol, a α/β-antagonist with antioxidant properties. The 6-min. walk test, the left ventricular ejection fraction, heart rate, plasma norepinephrine and malondialdehyde, a stress oxidative marker, concentrations were evaluated at baseline and after treatment for 6 months with carvedilol in 33 stable chronic heart failure patients with the Gln27→Gluβ2-adrenergic receptor polymorphism. Carvedilol significantly increased the left ventricular ejection fraction, while decreasing the heart rate and malondialdehyde plasma concentrations in chronic heart failure patients with the Glu 27β2-adrenergic receptor allele. There were however, no significant changes in patients with the Gln27β2- adrenergic receptor variant. © 2009 Nordic Pharmacological Society.